Mohammed Milhem

52.2k citations
225 papers · 6.8k indexed · 5 hit papers · h-index 38

Impact in

  • Oncology top 0.5%
    • CAR-T cell therapy research
    • Cancer Immunotherapy and Biomarkers
    • Vascular Tumors and Angiosarcomas
    • Cutaneous Melanoma Detection and Management
  • Immunology top 1%
    • Immunotherapy and Immune Responses

Papers in

    • CAR-T cell therapy research 61
    • Cancer Immunotherapy and Biomarkers 57
    • Vascular Tumors and Angiosarcomas 21
    • Cutaneous Melanoma Detection and Management 18

Mohammed Milhem

218 papers receiving 6.7k citations

Hit Papers

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials 2018 · 494 citations
49420122026201620212505007501000

Peers

Mohammed Milhem
Comparison fields: 5 of 130
  • Oncology 4.2k
  • Immunology 1.5k
  • Pulmonary and Respiratory Medicine 2.0k
  • Molecular Biology 2.5k
  • Genetics 969
Replace Pieter Demetter with:
Pieter Demetter Belgium
Masaki Mandai Japan
Ravi A. Madan United States
Matthew L. Sherman United States
Andrew G. Sikora United States
Michel Obéid Switzerland
Richard Lake Australia
Michele Del Vecchio Italy
Harry Hollema Netherlands
Tullia C. Bruno United States
Mohammed Milhem relative to Pieter Demetter Belgium Pieter Demetter's profile →
Citations per field
00.5×2.9×
Pieter Demetter · 1×
Citations per year

Countries citing papers authored by Mohammed Milhem

Since Specialization
Citations

This map shows the geographic impact of Mohammed Milhem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Milhem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Milhem more than expected).

Fields of papers citing papers by Mohammed Milhem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed Milhem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Milhem. The network helps show where Mohammed Milhem may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mohammed Milhem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mohammed Milhem Line = papers co-authored together Mohammed Milhem links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20250
3 20250
4 20241
5 20237
6 202318
7 20222
8 202215
9 20221
10 20215
11 20215
12 202117
13 201812
14 20180
15 20177
16
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Hit paper breakdown →
2016435
17 201623
18
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
Hit paper breakdown →
2015576
19 201559
20 201434

About Mohammed Milhem

Mohammed Milhem is a scholar working on Oncology, Biological Psychiatry, Immunology, Pulmonary and Respiratory Medicine and Biotechnology, having authored 225 papers that have together received 6.8k indexed citations. Recurring topics across this work include CAR-T cell therapy research (61 papers), Cancer Immunotherapy and Biomarkers (57 papers), Sarcoma Diagnosis and Treatment (50 papers), Immunotherapy and Immune Responses (38 papers), Melanoma and MAPK Pathways (26 papers), Virus-based gene therapy research (26 papers), Vascular Tumors and Angiosarcomas (21 papers) and Cutaneous Melanoma Detection and Management (18 papers). The work is most often cited by research in Oncology (4.2k citations), Immunology (1.5k citations), Pulmonary and Respiratory Medicine (2.0k citations), Molecular Biology (2.5k citations) and Genetics (969 citations). Mohammed Milhem has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Igor Puzanov, Claus Garbe, Howard L. Kaufman, Brian Andrew Van Tine, Lisa Chen, Robert H.I. Andtbacka, Omid Hamid, Yousef Zakharia, Varun Monga and Lev Demidov. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancers, Cancer Research and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026